Abstract: The present invention discloses a topical cream composition of eflornithine or its pharmaceutically acceptable salts or prodrugs thereof with lavender oil as penetration enhancer and other excipients, which is effective to reduce the rate of skin hair growth and studies pertaining to pharmacodynamic behaviour thereof on hair growth rate. The invention further discloses a process for preparing a topical composition in the form of oil-in-water emulsion based cream composition which comprises eflornithine or its pharmaceutically acceptable salts or prodrugs thereof with a penetration enhancer and other excipients.

Abstract: The present invention discloses a sustained release non-aqueous injectable composition of buprenorphine, its metabolite, its prodrug, or its salt thereof for the treatment of moderate-to-severe pain and opioid dependence. The non-aqueous injectable composition includes one or more biocompatible non-aqueous solvents, one or more release retarding agents, one or more surfactants, one or more biodegradable polymers and one or more stabilizers. The buprenorphine composition of the present invention delivers buprenorphine over a period of about one week to 12 weeks after single administration which leads to better patient compliance by reducing the daily dose administration of buprenorphine. The present invention also provides an injectable composition with potentially less pain due to the use of smaller gauge needles wherein the suitable gauge of needle may be 23 gauge to 30 gauge with a length of 8 to 30 mm. The preferred size of needle is 25 to 30 gauge.

Abstract: The invention discloses naltrexone implantable tablets which are devoid of metal salts and corticosteroids, and which provide consistent and controlled amount of naltrexone for 3 months or more; also disclosed is methods of treatment comprising the implants and methods of sterilization of the implants.

Abstract: The invention discloses naltrexone implantable tablets which are devoid of metal salts and corticosteroids, and which provide consistent and controlled amount of naltrexone for 3 months or more; also disclosed is methods of treatment comprising the implants and methods of sterilization of the implants.

Abstract: A method and apparatus for software controlled timing of embedded memory includes an embedded memory array and input/output (I/O) control circuitry coupled to the embedded memory array. The I/O control circuitry provides a plurality of I/O signals to the embedded memory array to control the input of data to the embedded memory array and output of data from the embedded memory array. The I/O control circuitry also includes programmable delay circuitry to alter the timing of the I/O signals.